More recently, to overcome resistant AML tumors, 225Ac-conjugated anti-CD33 (Actinium-225-lintuzumab) has been used in tandem with B cell lymphoma 2 selective inhibitor venetoclax to reduce antiapoptotic myeloid cell leukemia 1 overexpression [58]. This evidence concerns the gene CD33 and acute myeloid leukemia.